REFERENCES
- Krause A S, Weihrauch M R, Bode U, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high dose methotrexate therapy. Leuk Lymphoma 2002; 43: 2139–2143
- Verlooy J, Mosseri V, Bracard S, et al. Treatment of high risk medulloblastoma in children above the age of three years: a SFOP study. Eur J Cancer 2006; 42: 3004–3014
- Bacci G, Ferrari S, Longhi A, et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep 2003; 10: 851–857
- Joerger J M, Huitema A D, Van Den Bongard H J, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006; 62: 71–80
- Crom W R, Pratt C B, Green A A, et al. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol 1984; 2: 655–661